Interleukin-18 activates skeletal muscle AMPK and reduces weight gain and insulin resistance in mice

Febbraio, MA; Allen, TL; Lindegaard, B; Madsen, AN; Mortensen, OH; Alsted, TJ; Watt, MJ; Hidalgo, J; Syberg, S; Ditlevsen, S; Estevez, E; Rudnicka, C; Pilegaard, H; Abildgaard, J; Hojman, P; Matthews, VB; Pedersen, BK; Brandt, C; Bruce, CR
Abstract
Circulating interleukin (IL)-18 is elevated in obesity, but paradoxically causes hypophagia. We hypothesized that IL-18 may attenuate high-fat diet (HFD)-induced insulin resistance by activating AMP-activated protein kinase (AMPK). We studied mice with a global deletion of the α-isoform of the IL-18 receptor (IL-18R(-/-)) fed a standard chow or HFD. We next performed gain-of-function experiments in skeletal muscle, in vitro, ex vivo, and in vivo. We show that IL-18 is implicated in metabolic homeostasis, inflammation, and insulin resistance via mechanisms involving the activation of AMPK in skeletal muscle. IL-18R(-/-) mice display increased weight gain, ectopic lipid deposition, inflammation, and reduced AMPK signaling in skeletal muscle. Treating myotubes or skeletal muscle strips with IL-18 activated AMPK and increased fat oxidation. Moreover, in vivo electroporation of IL-18 into skeletal muscle activated AMPK and concomitantly inhibited HFD-induced weight gain. In summary, IL-18 enhances AMPK signaling and lipid oxidation in skeletal muscle implicating IL-18 in metabolic homeostasis.
Journal DIABETES
ISSN 0012-1797
Published 01 Sep 2013
Volume 62
Issue 9
Pages 3064-74
DOI 10.2337/db12-1095
Type Guidelines
Sponsorship
NHMRC: 526606, 1021168, 586698; Other